Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-negative Early Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00636441
What this trial is testing

Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer

Who this might be right for
Early-Stage Breast Cancer
Duke University 56
Testing effectiveness (Phase 2)Looking for participantsNCT06500208
What this trial is testing

Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC

Who this might be right for
Breast Cancer
Shanghai Jiao Tong University School of Medicine 48
Not applicableStudy completedNCT01446185
What this trial is testing

Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients

Who this might be right for
Breast Cancer
Genomic Health®, Inc. 100
Not applicableLooking for participantsNCT06106477
What this trial is testing

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

Who this might be right for
Breast Cancer
Medical College of Wisconsin 20
Not applicableLooking for participantsNCT07379918
What this trial is testing

Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer (Early Breast Cancer)Breast Cancer SurvivorsBreast Cancer Prognostic+2 more
Assistance Publique - Hôpitaux de Paris 1,000
Not applicableLooking for participantsNCT07084558
What this trial is testing

ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness

Who this might be right for
Early and Locally Advanced Breast Cancer
Austrian Breast & Colorectal Cancer Study Group 350
Testing effectiveness (Phase 2)UnknownNCT04499118
What this trial is testing

AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer

Who this might be right for
HER2-negative Breast Cancer
Sichuan Provincial People's Hospital 100
Large-scale testing (Phase 3)Ended earlyNCT05128773
What this trial is testing

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

Who this might be right for
Breast Cancer
Sanofi 3
Testing effectiveness (Phase 2)Looking for participantsNCT05020860
What this trial is testing

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmBreast Cancer Female+8 more
Baylor Breast Care Center 185
Testing effectiveness (Phase 2)Looking for participantsNCT04985266
What this trial is testing

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

Who this might be right for
ER+ Breast CancerHER2-negative Breast Cancer
Royal Marsden NHS Foundation Trust 1,100
Large-scale testing (Phase 3)Study completedNCT01985724
What this trial is testing

Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

Who this might be right for
Breast Cancer
Hellenic Oncology Research Group 650
Large-scale testing (Phase 3)Study completedNCT00309556
What this trial is testing

Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer

Who this might be right for
Breast Cancer
Austrian Breast & Colorectal Cancer Study Group 536
Not applicableStudy completedNCT07052734
What this trial is testing

Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients

Who this might be right for
Breast Cancer
Sun Yat-sen University 2,843
Testing effectiveness (Phase 2)Study completedNCT01548677
What this trial is testing

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer

Who this might be right for
Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastCirculating Tumor Cells
European Organisation for Research and Treatment of Cancer - EORTC 1,317
Testing effectiveness (Phase 2)Ended earlyNCT01919229
What this trial is testing

A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)

Who this might be right for
Early Breast Cancer
Novartis Pharmaceuticals 14
Testing effectiveness (Phase 2)Looking for participantsNCT06518837
What this trial is testing

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

Who this might be right for
Hormone Receptor-Positive Breast CancerHER2-Negative Breast Cancer
Rutgers, The State University of New Jersey 40
Not applicableStudy completedNCT05377684
What this trial is testing

Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment

Who this might be right for
Early-stage Breast Cancer
Ipsen 450
Testing effectiveness (Phase 2)UnknownNCT04247633
What this trial is testing

High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)

Who this might be right for
Breast Cancer
Samsung Medical Center 578
Testing effectiveness (Phase 2)Study completedNCT02273973
What this trial is testing

Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

Who this might be right for
Breast Cancer
Genentech, Inc. 334
Post-approval studies (Phase 4)Not Yet RecruitingNCT07630948
What this trial is testing

Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer

Who this might be right for
Breast CancerAdherence, Medication
Institute of Oncology Ljubljana 90
Next Page